Literature DB >> 9152065

Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders.

A M Abu el-Asrar1, J Van Damme, W Put, M Veckeneer, L Dralands, A Billiau, L Missotten.   

Abstract

PURPOSE: To investigate whether the chemokines monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) are involved in the pathogenesis of proliferative vitreoretinal disorders and to study their possible interaction with IL-6.
METHODS: In a prospective study of 125 consecutive patients (125 eyes), vitreous and paired serum samples were obtained and were assayed for MCP-1 and IL-8. Levels of IL-6 were determined by proliferation of the IL-6-dependent hybridoma cell line 7TD1.
RESULTS: Monocyte chemotactic protein-1 was detected in 13 (48%) of 27 vitreous samples from patients with retinal detachment, in five (63%) of eight samples from patients with macular pucker, in 31 (72%) of 43 samples from patients with proliferative vitreoretinopathy, and in 32 (76%) of 42 samples from patients with proliferative diabetic retinopathy, but not in samples from five patients with idiopathic epiretinal membrane. There was a significant (P = .049) correlation between the incidence of MCP-1 detection in retinal detachment, macular pucker, and proliferative vitreoretinopathy groups and the severity of proliferation. Interleukin-8 was detected in two vitreous samples from eyes with retinal detachment, in two samples from eyes with proliferative vitreoretinopathy, and in three samples from eyes with proliferative diabetic retinopathy. Monocyte chemotactic protein-1 levels in the vitreous samples were positively correlated with IL-6 levels (r = .31, P = .01). Interleukin-6 levels were significantly (P = .0097) greater in vitreous samples with than without detectable levels of MCP-1.
CONCLUSION: Monocyte chemotactic protein-1 is present in a substantial percent of vitreous samples from eyes with proliferative vitreoretinal disorders and may help in stimulating the infiltration of monocytes and macrophages into eyes with these disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152065     DOI: 10.1016/s0002-9394(14)71072-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  32 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  CXCR4 expression in vitreoretinal membranes.

Authors:  L Cabay; F Willermain; C Bruyns; J M Verdebout; Y Witta; J Baffi; T Velu; J Libert; L Caspers-Velu; A Maho; L Lespagnard
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

3.  Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy.

Authors:  Y Mitamura; S Takeuchi; A Matsuda; Y Tagawa; Y Mizue; J Nishihira
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

4.  Retinal detachment after posterior segment intraocular foreign body injuries.

Authors:  A M El-Asrar; S A Al-Amro; N M Khan; D Kangave
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

5.  How to keep photoreceptors alive.

Authors:  Alan Bird
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-06       Impact factor: 11.205

6.  The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy.

Authors:  Y Sassa; S Yoshida; K Ishikawa; R Asato; T Ishibashi; T Kono
Journal:  Eye (Lond)       Date:  2016-02-26       Impact factor: 3.775

7.  Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II.

Authors:  H Funatsu; H Yamashita; H Noma; T Mimura; K Sakata; S Hori
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

8.  Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes.

Authors:  Li Dong; Xiao Ying Lv; Bin Jie Wang; Ye Qing Wang; Hua Mu; Zhuo Lei Feng; Ping Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-09       Impact factor: 3.117

9.  Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases.

Authors:  Takeru Yoshimura; Koh-hei Sonoda; Mika Sugahara; Yasutaka Mochizuki; Hiroshi Enaida; Yuji Oshima; Akifumi Ueno; Yasuaki Hata; Hiroki Yoshida; Tatsuro Ishibashi
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

10.  Broad spectrum antiangiogenic treatment for ocular neovascular diseases.

Authors:  Ofra Benny; Kei Nakai; Takeru Yoshimura; Lauren Bazinet; James D Akula; Shintaro Nakao; Ali Hafezi-Moghadam; Dipak Panigrahy; Pouya Pakneshan; Robert J D'Amato
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.